HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 357 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,313,453 | +103704.9% | 86,740 | +38.7% | 0.02% | -32.0% |
| Q4 2022 | $3,192 | -99.9% | 62,557 | -3.0% | 0.02% | 0.0% |
| Q3 2022 | $3,005,000 | -5.0% | 64,525 | +2.1% | 0.02% | -3.8% |
| Q2 2022 | $3,164,000 | +12.8% | 63,192 | -2.5% | 0.03% | +30.0% |
| Q1 2022 | $2,806,000 | -3.9% | 64,802 | -25.6% | 0.02% | -4.8% |
| Q4 2021 | $2,921,000 | -15.7% | 87,123 | -2.3% | 0.02% | 0.0% |
| Q3 2021 | $3,464,000 | -10.1% | 89,133 | -11.1% | 0.02% | -8.7% |
| Q2 2021 | $3,855,000 | -25.2% | 100,222 | -1.9% | 0.02% | -25.8% |
| Q1 2021 | $5,157,000 | -0.6% | 102,204 | -2.5% | 0.03% | -6.1% |
| Q4 2020 | $5,187,000 | +357.8% | 104,798 | +187.7% | 0.03% | +312.5% |
| Q3 2020 | $1,133,000 | -0.7% | 36,423 | -11.2% | 0.01% | -11.1% |
| Q2 2020 | $1,141,000 | +20.0% | 41,034 | +1.0% | 0.01% | 0.0% |
| Q1 2020 | $951,000 | – | 40,615 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRAN CAPITAL MANAGEMENT, L.P. | 1,084,118 | $61,686,285 | 7.80% |
| SNYDER CAPITAL MANAGEMENT L P | 3,983,814 | $226,679,017 | 5.12% |
| First Light Asset Management, LLC | 923,119 | $52,525,471 | 4.88% |
| Redwood Investments, LLC | 441,809 | $25,138,932 | 3.37% |
| BERNZOTT CAPITAL ADVISORS | 444,728 | $25,305,023 | 3.27% |
| DOHENY ASSET MANAGEMENT /CA | 46,050 | $2,620 | 3.04% |
| Crawford Lake Capital Management, LLC | 42,171 | $2,399,530 | 2.75% |
| 2Xideas AG | 416,586 | $23,703,743 | 2.51% |
| Granite Investment Partners, LLC | 902,882 | $51,373,986 | 2.14% |
| HighMark Wealth Management LLC | 41,790 | $2,377,851 | 1.79% |